pharmacogenetics of leukemia treatment response richard aplenc may 2 nd , 2008
DESCRIPTION
Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008. Pediatric Leukemia. Most common pediatric malignancy Four types ALL AML CML JMML. Leukemia Treatment. Varies both by disease and treating group Generally curable ~80% in ALL ~60% in AML - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/1.jpg)
CCEB
Pharmacogenetics of Leukemia Treatment
Response
Richard AplencMay 2nd, 2008
![Page 2: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/2.jpg)
CCEBCCEB
Pediatric Leukemia
Most common pediatric malignancy Four types
ALL AML CML JMML
![Page 3: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/3.jpg)
![Page 4: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/4.jpg)
CCEBCCEB
Leukemia Treatment
Varies both by disease and treating group Generally curable
~80% in ALL ~60% in AML
Toxicity important Long term effects in ALL Infection and cardiac toxicity in AML
![Page 5: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/5.jpg)
CCEBCCEB
Leukemia Treatment
Multi-agent Over time Substantial impact on patient and family Accurate response prediction is clinically
very important
![Page 6: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/6.jpg)
CCEBCCEB
InductionInduction
ALL Therapy
ConsolidationConsolidation MaintenanceMaintenanceInterimInterim
MaintenanceMaintenanceDelayedDelayed
IntensificationIntensification
MTXMTXSteroidsSteroids 6-MP/6-TG6-MP/6-TG DoxorubicinDoxorubicin CyclophosphamideCyclophosphamideL-AspL-Asp VCRVCR AraCAraC
![Page 7: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/7.jpg)
CCEBCCEB
Predicting Treatment Response
Leukemic blast characteristics Morphology Cytogenetics Molecular alterations (BCR-ABL)
Patient characteristics Age Gender Genetic information?
![Page 8: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/8.jpg)
CCEBCCEB
Genetic Information
Variation in DNA sequence throughout the genome
Types of variation include Gene deletions (GSTT1) Duplications of DNA regions (TS 28 bp) Changes in single base pairs (SNPs)
Allele, genotype, haplotype
![Page 9: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/9.jpg)
CCEB
Allele/Genotype/Haplotype/CNV
SNP: Single Nucleotide Polymorphism
An allele is a single value for a single marker
A genotype is a pair of alleles for a given marker and both chromosomes in a single person
A haplotype is an ordered series of alleles for many markers on a single chromosome
Copy number variation (CNV) of DNA sequences
Chromosome from one parent
Chromosome from other parent
SNP 2
...Allele Genotype
Ha
plo
typ
e
SNP 1
GTGGGCGGGATGTACGTTCG
SNP example:
![Page 10: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/10.jpg)
CCEBCCEB
Impact of Genetic Variability
Loss of gene = loss of function Duplication of DNA segments and single
base pair changes may have different effects depending on position Gain of function, loss of function, no change
![Page 11: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/11.jpg)
Our Dream
One Genotype Would Explain Treatment Response
![Page 12: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/12.jpg)
CCEBCCEB
Why Did We Have This Dream?
Thiopurine methylatransferase (TPMT) Low frequency variants have complete loss of
thiopurine metabolizing abilities
![Page 13: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/13.jpg)
That Dream Has Ended
Why Is That?
![Page 14: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/14.jpg)
CCEB
![Page 15: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/15.jpg)
CCEB
![Page 16: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/16.jpg)
CCEB
TPMTOne Gene, One Pathway, One Exposure
OPO4CH2
SH
N
NN
N
OHHO
O
PO4CH2
SH
N
NN
N
OHHO
HO
N
N N
N
SH
H
N
N N
N
SH
HOH
N
N N
N
SH
HO
OH
H
Mercaptopurine
TIMP
TXMP
TGMPTPMT
6-MMP
TX
TUXO
N
N N
N
SCH3
H
Allopurinol
TPMT Deficiency
HGPRT
![Page 17: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/17.jpg)
CCEB
Two Remaining Questions
![Page 18: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/18.jpg)
Can we utilize data on host genetic variability in a clinically
meaningful way?
Question 1:
![Page 19: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/19.jpg)
Question 2:
Is Theo Zaoutis really Neo?
![Page 20: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/20.jpg)
Lisa Z looks like Trinity
This Makes Sense Because…
![Page 21: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/21.jpg)
And Because…
Paul Offit is clearly Morpheus
![Page 22: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/22.jpg)
CCEBCCEB
Now That Everyone is Awake…
Return to Question 1
![Page 23: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/23.jpg)
CCEBCCEB
Moving Towards the Answer
Decide on the question Understand the complex phenotype issues
Host genetics Environment
Address the genetic epidemiology issues
![Page 24: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/24.jpg)
CCEBCCEB
What is the Question?
Does the genotype inform us of the biology underlying a clinical outcome? Etiology
Does the genotype predict a clinical outcome? Prediction
![Page 25: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/25.jpg)
CCEBCCEB
One Conceptual Approach
Etiology Sensitivity Probability of positive test given disease
Prediction Positive predictive value Probability of disease given positive test
Seems obvious but impacts analysis
![Page 26: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/26.jpg)
CCEBCCEB
Complex Phenotype: Host Genetics
Common SNPs will have modest effects Potentially large impact for the population
Rare SNPs may have bigger effects Small population impact
SNP frequency and the effect size determine sample size
SNP frequency varies by ethnicity
![Page 27: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/27.jpg)
CCEBCCEB
Complex Phenotype: Environment
Identify and measure relevant covariates Genotype does not matter if the patient
doesn’t take the medication Concomitant medications
Drug-drug interactions
Alternative medications Folic acid supplimentation
Other environmental exposures
![Page 28: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/28.jpg)
CCEBCCEB
What are the Genetic Epidemiology Issues?
Population stratification Variation of SNP frequency by ethnicity
High dimensional data Gene-environment interactions
Interaction of host genetics with environment
Gene-gene interactions Interaction of different SNPs
Multiple comparisons
![Page 29: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/29.jpg)
CCEBCCEB
Some Examples from Our Data
Methotrexate interrupts the folate cycle ALL blasts are sensitive to folate depletion Polymorphisms in genes in the folate cycle
may impact methotrexate efficacy
![Page 30: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/30.jpg)
p = 0.0486
0.50
0.60
0.70
0.80
0.90
1.00
0 5 1015Years
Wildtype (C) Variant (T)
Relapse Free Survival by MTHFR C677T Variant Allele
![Page 31: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/31.jpg)
CCEBCCEB
MTHFR C677T Cox Model
Covariate HR p 95% CIC677T variant 1.93 0.004 1.229 3.037
Day 7 BM 1.77 0.013 1.125 2.773
Age 1.11 0.016 1.020 1.220
Race 1.71 0.307 0.610 4.798
Gender 1.37 0.238 0.811 2.323
Rx Arm 1.18 0.214 0.908 1.535
WBC 0.99 0.335 0.971 1.010
Phenotype 0.95 0.776 0.661 1.362
![Page 32: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/32.jpg)
CCEBCCEB
![Page 33: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/33.jpg)
CCEBCCEB
MTHFR C677T and Infection Risk
Num.Infection
C/C 224 46 Sepsis 1
C/T 187 42 Sepsis 1.13 0.700-1.818
T/T 72 16 Sepsis 1.13 0.585-2.188
C/C 224 155 Fever/Neutropenia 1
C/T 187 120 Fever/Neutropenia 0.83 0.546-1.276
T/T 72 53 Fever/Neutropenia 1.32 0.709-2.447
C/C 224 123 Infection - Other 1
C/T 187 113 Infection - Other 1.27 0.850-1.887
T/T 72 43 Infection - Other 1.2 0.690-2.087
0.49
0.86
0.34MTHFR C677T
MTHFR C677T
OR 95% CI P value
MTHFR C677T
Gene Genotype N Infection Type
![Page 34: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/34.jpg)
CCEBCCEB
MTHFR Conclusions
The MTHFR C677T variant allele seems to impact relapse risk
Dose adjustment of methotrexate for toxicity/infection does not ameliorate this effect
Dose adjustment based on genotype may be clinically useful
Replication in anther sample set is ongoing
![Page 35: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/35.jpg)
CCEBCCEB
MTFHR Issues
Allele versus genotype versus haplotype Clinically meaningful analysis
Positive predictive value
![Page 36: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/36.jpg)
p = 0.0486
0.50
0.60
0.70
0.80
0.90
1.00
0 5 1015Years
Wildtype (C) Variant (T)
Relapse Free Survival by MTHFR C677T Variant Allele
![Page 37: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/37.jpg)
CC vs TT, p = 0.0477
0.50
0.60
0.70
0.80
0.90
1.00
0 5 1015Years
Wildtype (CC) Heterozygote (CT)Variant (TT)
Relapse Free Survival by MTHFR C677T Genotype
![Page 38: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/38.jpg)
0.00
0.25
0.50
0.75
1.00
0 5 10 15analysis time
CA CA CA CGCG CG TA CA
TA CG TA TATA TG TG CGTG TG
Kaplan-Meier survival estimates, by haplo
![Page 39: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/39.jpg)
CCEBCCEB
PPV with Time to Relapse Data
This is the metric of interest to oncologists Moscowitz and Pepe defined positive
predictive value in survival time data PPVXk(t) = P(T ≤ t | Xk = 1)
![Page 40: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/40.jpg)
![Page 41: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/41.jpg)
![Page 42: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/42.jpg)
CCEBCCEB
PPV Conclusions
Although statistically significant, the MTHFR C677T allele has a PPV of 35% This is worse than flipping a coin Important question is the increased predictive
value above baseline
![Page 43: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/43.jpg)
CCEBCCEB
TS 28 bp as Example
N RFS HR CI p
2R/2R 83 80% 1 -- --
2R/3R 196 79% 1.68 0.863-3.255 0.13
3R/3R 103 73% 1.87 0.942-3.721 0.074
3R/4R 20 60% 3.69 1.436-9.481 0.007
![Page 44: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/44.jpg)
![Page 45: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/45.jpg)
CCEBCCEB
TS 28 bp Bootstrapping
Does knowledge of TS genotype improve prediction of relapse?
Bootstrap comparison of relapse free survival of all patients with those with particular TS polymorphisms
No additional predictive value from knowing TS genotype Caveat of sample size issues
![Page 46: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/46.jpg)
CCEBCCEB
Other Genetic Epidemiology Issues Multiple comparisons Gene-gene and gene-environment
interactions
![Page 47: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/47.jpg)
CCEBCCEB
Multiple Comparisons
Probability of finding a false association by chance = 1 - 0.95n
n = 10, p = 40% n = 100, p = 99.4%
Our data: 19 genotypes, 2 genders, 3 different relapse
sites N = 228, p = 99.99959%
![Page 48: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/48.jpg)
CCEBCCEB
Methods for Multiple Comparisons
Ignore it Validation sample set Adjust p-values
Bonferroni False discovery rate (FDR) Benjamini et al 2001
Use Bayesian methods False positive report probability (FPRP) Wacholder et al 2004
![Page 49: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/49.jpg)
CCEBCCEB
High Dimensional Data
The number of cells (N) needed to split R variables into X partitions:
N = XR
A single 2-way combination R = 2, X= 3, N= 9
We have evaluated 19 genotypes All 2-way combinations of our genotypes
R = 19, X = 3, N = 1,162,261,467
![Page 50: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/50.jpg)
CCEBCCEB
High Dimensional Data Methods
Several methods in current use We have used patterning with recursive
partitioning (CART) Create groups as uniform as possible Use with genotype and other covariates
No p-values Confirmation by cross-validation within the
sample set
![Page 51: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/51.jpg)
CCEB
![Page 52: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/52.jpg)
CCEBCCEB
CART Caveats
No p-values Need to validate in a separate sample Often difficult to interpret results,
particularly of higher order interactions i.e. 2 genotypes and 1 environmental factor
![Page 53: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/53.jpg)
CCEBCCEB
Future Directions
Validate and extend genotyping in another ALL sample set Incorporate drug dose data
Investigate the impact of genetic variability on infection risk in pediatric myeloid leukemia R01 resubmission with Theo Zaoutis
![Page 54: Pharmacogenetics of Leukemia Treatment Response Richard Aplenc May 2 nd , 2008](https://reader036.vdocuments.us/reader036/viewer/2022062409/56814d57550346895dba90a0/html5/thumbnails/54.jpg)
CCEB
The End….
Thanks to everyone who makes it safe to swim with the sharks. Bev Lange, Tim Rebbeck,Jinbo Chen, Theo Zaoutis, Tom McWilliams, Peggy Han, Shannon Smith, Michelle Horn, Melanie Doran. Funded by RO1 CA108862-01.